PHRM 324 Longitudinal Case Script

1) PATIENT IDENTIFICATION (ID):

Today I’m assessing RL, a 37-year-old female with a complex urologic and chronic pain history. She has a long-standing suprapubic catheter, chronic bladder pain, recurrent UTIs, and significant polypharmacy, along with multiple mental health comorbidities including anxiety, depression, binge-eating disorder, and borderline personality disorder.

2) CHIEF COMPLAINT:

RL presents today for a comprehensive medication review and assessment of her chronic bladder pain, recurrent urinary tract infections, and escalating polypharmacy concerns, with the goal of optimizing symptom control while improving medication safety.

3) HISTORY OF PRESENT ILLNESS (HPI):

RL has had chronic bladder pain for several years, associated with interstitial cystitis and overactive bladder. Her pain is severe, with baseline intensity around 7 out of 10, worsened by movement and daily activities. She relies on a suprapubic catheter, changed approximately monthly.

She experiences frequent bladder spasms, urinary urgency, right flank discomfort, and episodes that feel like UTIs. However, her recent ED assessments show that many episodes are pain flares rather than true infections.

She has a history of recurrent UTIs—often monthly—frequently with Klebsiella, and a past infection with Pseudomonas. She is managed primarily with IV ertapenem, as she has numerous antibiotic allergies including ciprofloxacin, TMP-SMX, macrolides, nitrofurantoin, and clindamycin.

RL recently underwent bladder Botox injections in December 2022 and again in February 2025. Despite some improvement, pain and spasms continue. According to pelvic floor physiotherapy reports, she has significant pelvic floor dysfunction, with poor relaxation and coordination, though this improved roughly 50% with therapy. Bladder spasms remain her major barrier to functioning.

RL’s symptoms often trigger secondary nausea, and she has overlapping migraine flares approximately four times per month.

There have been multiple ED visits from March to April 2025 for bladder pain.

4) PAST MEDICAL & SURGICAL HISTORY:

“RL has an extensive and medically complex past medical history that contributes significantly to her current presentation. Her primary and most limiting condition is interstitial cystitis and bladder pain syndrome, which has been longstanding and refractory to multiple therapies. She also has overactive bladder and chronic urinary retention, and she has required a suprapubic catheter, with multiple catheter insertions and monthly changes.

She experiences recurrent urinary tract infections, historically occurring about once a month, and her microbiology profile includes Klebsiella species and a prior Pseudomonas infection in 2022, which significantly restricts treatment options. Her suprapubic catheter dependence and chronic inflammation make it difficult to distinguish infection from bladder pain flares.

Beyond her urologic history, RL also has chronic neuropathic low-back pain and sciatica, which contributes substantially to her opioid and CNS-depressant use. She also experiences chronic migraines, approximately four times per month.

Her medical history is also notable for morbid obesity with a BMI of 40.2, which affects mobility, contributes to pain, and complicates bladder symptom management. She is also documented as an MRSA carrier.

From a laboratory perspective, she has a high B12 level, reflecting unnecessary supplementation, and probable iron deficiency, with ferritin levels around 20–21 micrograms per liter. These findings correlate with chronic PPI use and intermittent reduced intake during pain flares.

Psychiatric comorbidities are also an important part of RL’s history. She has depression, anxiety, borderline personality disorder, binge eating disorder, and a history of self-harm. These conditions influence how she experiences pain, how she responds to medications, and her overall functional status. She also takes Vyvanse for binge eating disorder with good effect.
Additionally, she previously underwent a lumbar puncture with a documented elevated opening pressure.

In terms of surgical history, RL has undergone several procedures. She has had multiple suprapubic catheter insertions, reflecting ongoing urinary retention. She has also had cystoscopies with bladder Botox injections in 2022 and 2025, which provided partial relief but not full symptom control.

She has undergone both colonoscopy and gastroscopy in 2020 and again in 2024 as part of her GI workup. gynecologically, she underwent a hysteroscopy with dilation and curettage in 2023.

RL has also had a cholecystectomy, and her past records include several orthopedic surgeries, indicating a history of musculoskeletal injury and chronic pain.

Altogether, RL’s past medical and surgical history paints a picture of a young patient with multiple overlapping pain syndromes, chronic bladder dysfunction, recurrent infections with limited treatment options, metabolic concerns, and significant psychiatric comorbidity, all of which interact to influence her current challenges and medication complexity.”

5) MEDICATION HISTORY:

“Given the complexity of RL’s medication list, I’ll summarize her therapies by category and highlight the most clinically important points, including what we learned from interviewing her and reviewing the chart.

1. Bladder, OAB, and Spasm Management

RL is on several medications targeted at bladder pain, overactive bladder symptoms, and catheter-related spasms.

She uses hyoscine butylbromide 10 mg every 8 hours as needed, primarily during bladder spasm episodes. She reports that this does help somewhat with cramping, although not consistently enough to prevent her ED visits.

She has also used solifenacin 5 mg daily, and she reports that this medication was helpful for reducing urgency and frequency. However, she finds it expensive and often cannot afford to take it consistently, so adherence is variable.

She is not currently using methenamine, and there is no evidence from the chart or from her interview that she has been on suppressive therapy recently.

Finally, she is taking colchicine 0.6 mg daily, originally prescribed for knee pain in the past. RL reports that she no longer has joint pain, which means colchicine is no longer clinically indicated, but she has continued taking it simply out of habit.

2. Pain and Neuropathic Pain Management

This is one of the largest and most complex areas of her regimen.

For neuropathic pain, she takes gabapentin 1200 mg three times daily, which is a high but still safe dose. She reports that this does help with her sciatica and neuropathic back pain.

She uses cyclobenzaprine 10 mg at bedtime as needed, mainly for muscle tension. However, RL noted that it has not been helpful for bladder spasms, and she often feels sedated by it.

Her opioid exposure is significant. She uses:

  • Morphine immediate-release 5 mg every 6 hours as needed — usually one tablet per day.

  • Morphine long-acting 15 mg daily as needed, though she often takes one capsule daily, functioning more like a scheduled medication rather than PRN.

  • Tylenol #3, one to two tablets every four hours as needed, limited to 40 tablets per month.

  • Hydromorph 1 mg/mL oral solution, used occasionally during severe flares.

  • Naproxen 500 mg twice daily as needed.

  • Ketorolac 10 mg twice daily as needed, although this should be time-limited and she does not appear to be using it chronically.

From our interview, RL clarified that she relies heavily on opioids during catheter changes, and that morphine provides the most relief for her bladder pain. However, this has created a pattern where her PRN opioids are functioning like scheduled medications, contributing to significant CNS load and sedation.

3. Nausea Management and CNS / Psychiatric Medications

For nausea related to pain flares and migraines, RL uses nabilone 1–2 mg three times daily, which she finds very effective. However, nabilone significantly increases her sedation, especially when combined with opioids, gabapentin, hydroxyzine, and benzodiazepines.

She takes ondansetron ODT 4 mg as needed, typically one to two tablets per week.

For sleep, she uses hydroxyzine 10 mg at bedtime as needed, which she finds helpful on stressful nights. She typically uses this one to two nights per week.

For anxiety, she uses lorazepam 1 mg sublingually as needed, up to 10 tablets per week, which translates to near-daily use.

For mood and neuropathic pain, she takes duloxetine 90 mg daily, separated as 60 mg and 30 mg doses in the morning. RL reports that her mood is stable, and she does not currently have active symptoms of depression, anxiety, or her history of borderline personality disorder.

4. Migraine Therapy

For migraine prophylaxis, she is on propranolol 80 mg twice daily, supplied in a weekly blister pack to ensure adherence. She takes this regularly and consistently.

For acute migraine attacks, she uses sumatriptan nasal spray, approximately four times per month, and finds this effective.

5. Gastrointestinal, Stimulant, and Miscellaneous Medications

RL takes rabeprazole 20 mg twice daily for chronic reflux, which she has been on long-term.

She takes Vyvanse 60 mg daily for binge eating disorder and finds it effective for appetite regulation and daytime functioning.

She also uses nasal corticosteroids—beclomethasone and mometasone—for allergic rhinitis, as well as topical tretinoin, and nystatin for thrush episodes. She uses betahistine as needed for vertigo.

Finally, she had been taking vitamin B12 supplements, although her levels are significantly elevated and she does not require ongoing supplementation.

6) ALLERGIES AND INTOLERANCES:

“RL has several documented allergies and medication intolerances.

She has an intolerance to macrolides, with the adverse reaction tocumented being tachycardia. 

She also has a moderate allergy to acetazolamide, which caused urticaria when she took it.

She has some sort of a intelerance or allergy to topirmate, although it wasn’t clearly documented, where she developed hives and experienced nausea/vomiting.

She has a severe allergy to sulfamethoxazole–trimethoprim, which caused urticaria and itching at the time of exposure.

She has a severe reaction to ciprofloxacin, specifically the opthalmic drop formulation where she experienced urticaria. 

In addition, she has a severe allergy to tramadol, which resulted in urticaria and peripheral edema.

7) SOCIAL HISTORY:

“In terms of RL’s social history, her chronic bladder symptoms and ongoing pain have had a significant impact on her daily functioning and quality of life. She shared that she is no longer able to participate in the hobbies she previously enjoyed, including swimming and playing in a band, because prolonged movement and activity tend to aggravate her bladder pain and catheter discomfort.

She lives with chronic pain and functional limitations, which affect both her mobility and her ability to engage in routine activities outside the home.

Financially, RL experiences ongoing cost-related barriers, particularly when it comes to medications. For example, solifenacin has been helpful, but she often cannot afford it consistently, which affects her ability to manage her bladder symptoms effectively.

There is no documented tobacco or alcohol use, and nothing in her chart suggests substance misuse outside of her prescribed medications.”

🩺 9) Review of Systems & Physical Exam (Head-to-Toe Format)

VITALS: (Most Recent March 11, 2025)

“In terms of RL’s most recent vital signs, she is hemodynamically stable. Her blood pressure is 106 over 55, which is low-normal for her age, and may reflect the cumulative effect of her sedative medications, including opioids, gabapentin, hydroxyzine, lorazepam, and nabilone. Importantly, hypotension together with tachycardia would make me more concerned about sepsis, but her heart rate was 65, which is normal and on the lower side, likely influenced by her propranolol therapy. In infection, we’d expect HR > 90, so this supports that this is more likely a pain flare rather than an infection. 

Her respiratory rate was 16 breaths per minute, and her oxygen saturation was 95 percent, both of which are reassuring given her high CNS-depressant burden polypharmacy burden, showcasing that there’s no evidence of respiratory depression at the time of measurement.  Her temperature was 36.7, so afebrile. This also supports non-infectious bladder pain as something such as pyelonephritis would more typically produce a fever. 

Overall, her vitals show no evidence of systemic infection or acute deterioration, and they support the impression that her symptoms during recent visits were likely due to bladder pain flares rather than an active urinary tract infection.”

CNS/Neurologic:

“From a neurological standpoint, RL has several important issues that contribute significantly to her overall clinical complexity. First, she experiences chronic migraines, averaging about four per month. She is using sumatriptan nasal spray appropriately for acute attacks and propranolol 80 mg twice daily as migraine prophylaxis. Her migraines are often accompanied by nausea, which drives intermittent use of ondansetron and contributes to her frequent reliance on nabilone.

In addition to migraines, RL has chronic neuropathic low-back pain and sciatica, which has been ongoing for several years. She is currently treated with gabapentin and duloxetine, both of which are appropriate first-line options for neuropathic pain. However, when combined with her other medications, they greatly increase her overall sedation burden.

Despite these chronic pain symptoms, her neurological assessments during multiple emergency department visits have all been normal, with no focal deficits, no alterations in mental status, and no neurological red flags documented.

However, the biggest concern in the neurologic system is actually her CNS polypharmacy. RL is on a very large number of CNS depressants concurrently, including:

  • Opioids (multiple formulations),

  • Lorazepam,

  • Hydroxyzine,

  • Cyclobenzaprine,

  • Nabilone,

  • and high-dose gabapentin.

This combination significantly increases her risk for somnolence, cognitive impairment, falls, and respiratory depression. It also makes deprescribing more challenging, because several of these medications overlap in mechanism and withdrawal risks.

So in summary, while RL’s neurological examinations are consistently normal, her medication regimen places her at substantial, ongoing neurologic safety risk, and likely contributes to her fatigue, sedation, and impaired function across the day.

HEENT (Head, Eyes, Ears, Nose, Throat):

“For HEENT, there are no documented abnormalities. RL does use nasal corticosteroids such as beclomethasone and mometasone, suggesting a history of allergic rhinitis. There are no reports of sinus tenderness, vision changes, or oral issues.

This is relevant because sinus congestion can sometimes worsen migraines, but there is nothing in her HEENT review to suggest that any of her current symptoms are originating from this region.”

Cardiovascular (CVS):

“Cardiovascularly, RL appears stable. She has no documented history of heart disease, arrhythmias, or edema. Her blood pressure and heart rate remain low-normal, again likely secondary to propranolol therapy.

It’s important to note that beta-blockers like propranolol can mask tachycardia, which is a classic sign of infection; therefore, even in the absence of tachycardia, we need to use other infection markers to differentiate a bladder flare from a true UTI. In her case, the absence of fever, stable vitals, and normal white counts consistently point away from systemic infection.”

Respiratory:

“From a respiratory standpoint, RL’s examination and history are both reassuring. She has a normal respiratory rate, and her most recent oxygen saturation was 95 percent, which is acceptable and does not indicate any acute compromise. She has no shortness of breath, no cough, no wheeze, and no history of chronic lung disease, and there is no documentation of any recent respiratory infections.

Even though her respiratory exam appears normal, this is one of the systems where I remain particularly cautious. RL is on a very high sedative burden, including multiple opioids, lorazepam, nabilone, hydroxyzine, and high-dose gabapentin. This level of CNS depressant polypharmacy significantly increases her risk of respiratory depression, especially at night or during acute pain flares when she may increase her PRN dosing.

The fact that her respiratory exam and vitals are stable is reassuring in the short term, but it does not eliminate the underlying risk. For this reason, her respiratory status is an important safety consideration when planning any deprescribing strategy or when modifying her pain management regimen. Overall, while there are no acute respiratory concerns today, her medication profile places her at chronic elevated risk, and close monitoring is warranted.”

Gastrointestinal (GI):

“Gastrointestinally, RL experiences frequent nausea, and this is typically triggered by her pain flares rather than by gastrointestinal disease. This pattern explains her intermittent use of ondansetron and her more regular use of nabilone, which she finds helpful when her bladder pain escalates.

She also has chronic GERD, which is well controlled on rabeprazole twice daily. She has no documented vomiting or diarrhea during her recent emergency department visits, and her abdominal examinations have consistently been soft and non-tender, with no signs of acute abdomen.

Her liver enzymes — ALT, ALP, and GGT — have remained within normal limits, indicating that there is no hepatic dysfunction contributing to her symptoms or interfering with her medication metabolism. One important point is that long-term proton pump inhibitor therapy, such as rabeprazole, can reduce gastrointestinal iron absorption, and this may be contributing to her low ferritin levels, which were in the 20–21 microgram per liter range.

So overall, her GI symptoms are most likely a secondary effect of chronic pain, rather than a primary gastrointestinal pathology, but the impact of her PPI therapy on iron status is clinically relevant and will need to be addressed in her management plan.”

Genitourinary (GU):

“In terms of the genitourinary system, this is the most important and clinically complex area for RL. She has a longstanding suprapubic catheter, which is changed approximately monthly, and she experiences significant chronic suprapubic and bladder pain associated with this. Her baseline pain is around seven out of ten, and this level of discomfort significantly limits her day-to-day functioning.

Her symptoms include persistent urgency, bladder spasms, right-sided flank discomfort, and episodes that feel to her like urinary tract infections. She has had multiple emergency department visits over the past several months for what she believed were UTIs; however, during these visits she has remained afebrile, her vital signs have been stable, and her white blood cell counts have been normal, suggesting there is no systemic bacterial infection.

Her urine dips during these flares typically show only trace blood or leukocytes, which is expected in individuals with chronic catheter use, and is not specific for infection. Her CRP levels have been chronically mildly elevated — ranging from 5 to 23 milligrams per liter — which is consistent with chronic inflammation from bladder irritation and her underlying condition, rather than an acute infectious process.

RL’s underlying bladder diagnoses include interstitial cystitis, overactive bladder, and chronic urinary retention. She has undergone bladder Botox injections in both 2022 and again in February 2025. She also has documented pelvic floor dysfunction, which initially showed poor relaxation and coordination but improved by about 50 percent with physiotherapy, although bladder spasms remained a major issue.

She does have a history of recurrent true UTIs, particularly with Klebsiella species, and she had a documented Pseudomonas UTI in 2022. However, her more recent ED presentations appear to be bladder pain flares rather than active infections. Complicating her UTI management is a long list of antibiotic allergies, including ciprofloxacin, macrolides, nitrofurantoin, TMP-SMX, and clindamycin, which severely restricts the number of safe oral treatment options. As a result, she has often required IV ertapenem for treatment of confirmed infections.

Overall, RL’s GU findings strongly suggest that the majority of her current symptoms are being driven by chronic bladder pain syndrome and catheter-related irritation, rather than acute bacterial infection. The presence of chronic CRP elevation further supports this inflammatory picture. Going forward, careful differentiation between true infection and non-infectious flares will be essential, and her antibiotic allergies significantly influence the feasibility of future UTI management strategies.”

Musculoskeletal (MSK):

“Musculoskeletally, RL’s primary issue is her chronic neuropathic low-back pain and sciatica, which has been ongoing for several years and contributes significantly to her overall symptom burden. She is currently treated with gabapentin, duloxetine, cyclobenzaprine, and multiple opioid formulations, each targeting different aspects of her pain. There are no acute musculoskeletal abnormalities documented in her ED assessments — no red-flag signs such as weakness, saddle anesthesia, or new gait disturbance.

The challenge here is that RL’s pain originates from multiple sources — neuropathic pain, chronic bladder pain, and musculoskeletal discomfort — and this combination has driven her opioid use upward over time. Importantly, opioids are not ideal for neuropathic pain, and they offer limited benefit for chronic sciatica compared to agents like gabapentin and duloxetine. This supports the need for a structured deprescribing approach focused on minimizing medications that provide low value.

Additionally, RL continues to use cyclobenzaprine, which adds to her sedation burden while offering relatively minimal therapeutic benefit, as she reports it has not been effective for her bladder spasm symptoms. Taken together, her MSK picture highlights how her chronic pain conditions have contributed to escalating polypharmacy, and this reinforces the importance of optimizing non-opioid therapies while reassessing medications that may no longer be providing meaningful benefit.”

Dermatologic (DERM):

“Dermatologically, there are no active concerns. She uses topical tretinoin for acne. There is no documentation of rashes, ulcers, or skin infections. This is relevant because several of her antibiotic allergies present as rashes, but there are no current dermatologic findings suggesting an active allergic process or catheter-site infection.”

Endocrine:

“Endocrine review is unremarkable. Her thyroid-stimulating hormone is 1.01, which is normal. Her hemoglobin A1c is 4.9 percent, so she does not have diabetes. There is no evidence of adrenal or thyroid dysfunction, and none of her symptoms appear to be endocrine-related.”

Electrolytes / Metabolic Panel:

“Looking at RL’s electrolytes and metabolic panel from January through April 2025, her results have been largely stable and reassuring. Her sodium levels have consistently been between 140 and 143, and her chloride between 103 and 105, both of which fall comfortably within the normal range.

She did have one slightly elevated potassium at 5.3, but because her kidney function is normal, this is most consistent with a transient potassium shift rather than a true hyperkalemic process. It may also have been influenced by hemolysis or acute stress during a pain flare. All subsequent potassium readings returned to normal.

Her bicarbonate has been mildly elevated at 32 to 34, which represents a pattern of mild metabolic alkalosis. This could be related to chronic hyperventilation during severe pain episodes or, alternatively, from intermittent decreased oral intake or nausea, both of which she experiences frequently. There is no evidence of a primary metabolic disorder.

In terms of renal function, her creatinine ranges from 60 to 78 µmol/L, and her eGFR has consistently been between 84 and 112 mL/min, indicating normal, stable kidney function. This is clinically important because patients with recurrent urinary tract infections or chronic catheter use can develop renal impairment over time, but RL currently has no signs of kidney damage. It also means she can safely use medications such as anticholinergics without requiring renal dose adjustments.

Her liver function tests — including ALT, ALP, GGT, and bilirubin — are all normal, confirming that she does not have any hepatic dysfunction contributing to her pain, nausea, or medication metabolism.

Lastly, her random glucose values between 5.6 and 6.1 mmol/L are normal, and her A1c is 4.9 percent, confirming that she is not diabetic and does not have any endocrine-related cause for her symptoms.

Overall, her metabolic and organ function labs are stable and reassuring. The main abnormalities—namely the single elevated potassium and mild metabolic alkalosis—are minor, transient, and clinically explainable within the context of her chronic pain condition, rather than indicating any underlying organ dysfunction.”

PERTINENT LABS:

“Looking at RL’s pertinent labs, her complete blood count has been consistently normal across multiple encounters. Her white blood cell count ranges from 7 to 8.6, which strongly supports that she has not had a systemic bacterial infection during her recent pain flares. This is important because her symptoms often mimic UTIs, but her normal WBC count tells us that she is not mounting a systemic inflammatory response. Her hemoglobin has remained between 125 and 137, so she is not anemic, and this also means her fatigue and low energy are unlikely to be blood-related. Her platelet count has remained between 218 and 279, which is normal and does not indicate any inflammatory thrombocytosis or bone marrow stress.

Her C-reactive protein has fluctuated between 4 and 23 milligrams per liter. This mild to moderate elevation is very typical for someone with chronic bladder pain syndrome, catheter irritation, and ongoing pelvic inflammation. A CRP of 23 is elevated but not nearly high enough to suggest acute bacterial pyelonephritis, which would typically push CRP levels above 40 or 50. So again, her inflammatory markers support chronic irritation, not acute infection.

Her iron studies show a ferritin of 20 to 21 micrograms per liter, which indicates probable iron deficiency. This may contribute to her fatigue and overall low energy. The likely contributors are her long-term PPI therapy, which reduces gastric iron absorption, and her reduced nutritional intake during severe pain days. Iron supplementation would be appropriate.

In contrast, her vitamin B12 level is 1061, which is significantly above the normal range and reflects unnecessary supplementation. This is not harmful but offers no clinical benefit, so discontinuing B12 is appropriate.

Finally, her pregnancy test is negative, which is essential to confirm because she is using medications such as nabilone, opioids, and triptans, all of which require strong caution or avoidance in pregnancy. This ensures that her current medication regimen is safe to continue from a reproductive standpoint.

Overall, her labs provide a very consistent picture: she does not have signs of acute infection, she has chronic low-grade inflammation driven by bladder pathology, and she has iron deficiency that needs treatment while B12 supplementation should be stopped.”

MICROBIOLOGY:

“Looking at RL’s microbiology history, she has a well-documented pattern of recurrent urinary tract infections, most commonly caused by Klebsiella species, which in the past have been sensitive to ertapenem. She also has a history of Pseudomonas infection from 2022, which is particularly important because Pseudomonas narrows her antibiotic options even further given her multiple allergies.

One challenge in her recent presentations is that no urine culture and sensitivity tests have been sent during her most recent episodes. As a result, we don’t have any contemporary isolates to guide therapy, which makes assessment and antimicrobial planning more difficult.

Another key point is that RL has a chronic suprapubic catheter, and this significantly complicates interpretation of urine results. Patients with long-term catheters almost always have some degree of bacterial colonization, and this does not necessarily represent true infection. It also means that findings like trace leukocytes or blood on urinalysis are expected and often reflect catheter irritation rather than active UTI.

So overall, when we look at her infection history in context, RL’s pattern suggests a mix of chronic colonization with intermittent true infections, but her most recent symptoms and labs are more consistent with non-infectious bladder pain flares rather than acute bacterial disease.”

“My primary drug therapy concerns for RL, prioritized from safety downward, include several issues related to her complex medication regimen and her overlapping chronic pain and bladder conditions.

1. Safety Concerns

First, RL has significant CNS depressant stacking. She is taking multiple sedating medications at the same time — including two formulations of morphine, Tylenol #3, hydromorph, lorazepam, cyclobenzaprine, hydroxyzine, gabapentin at high doses, and scheduled nabilone. Taken together, this combination places her at substantial risk of sedation, impaired cognition, falls, and respiratory depression, especially overnight or during pain flares when she increases her PRN use.

Second, she has poly-opioid exposure with several opioids being used interchangeably and, in some cases, functionally on a scheduled basis. This increases the risk of opioid toxicity, additive respiratory depression, and complicates any future tapering plan.

Third, she has multiple NSAIDs available PRN, including naproxen and ketorolac. Ketorolac in particular should only be used very short-term, but it appears intermittently available to her, creating risk for kidney injury or GI bleeding.

Fourth, RL has a high anticholinergic burden from solifenacin, hyoscine, and cyclobenzaprine. This increases her risk of constipation, dry mouth, cognitive impairment, urinary retention, and worsening bladder symptoms.

Fifth, her chronic use of a PPI — rabeprazole twice daily — appears to be contributing to her iron deficiency, as her ferritin is consistently low. Long-term high-dose PPI therapy also increases the risk of B12 deficiency, fractures, and infections.

Sixth, several of her medications interact pharmacodynamically to increase sedation. For example, nabilone interacts with opioids, benzodiazepines, hydroxyzine, gabapentin, and muscle relaxants, amplifying CNS depression. She also has a high benzodiazepine load with near-daily lorazepam use.

2. Effectiveness Concerns

Moving to effectiveness, cyclobenzaprine has not been effective for RL’s bladder spasm symptoms, and she reports no benefit from it.

Solifenacin has partial benefit for frequency and urgency but is underused due to cost, meaning she is not getting the full therapeutic effect.

Her long-acting morphine is listed as PRN but is used almost daily, meaning it is not being used in a manner that maximizes its sustained-release benefit.

Gabapentin and duloxetine are appropriate for neuropathic pain, but her neuropathic symptoms remain severe, suggesting that her overall regimen may not be fully optimized.

3. Indication Concerns

She remains on colchicine, despite no current joint pain and no inflammatory condition requiring treatment. This medication is no longer indicated.

She continues to take vitamin B12 supplementation, despite having extremely high serum B12 levels and no deficiency.

She has probable iron deficiency, which is not currently being treated.

Given her recurrent bladder flares, she would benefit from an updated urine culture and sensitivity, but this has not been performed recently.

She would also benefit from revisiting non-pharmacologic strategies such as pelvic floor physiotherapy, which previously improved her symptoms but has not been resumed.

4. Adherence Concerns

Finally, from an adherence standpoint, RL’s regimen is extremely complex, with numerous PRN medications that effectively function as scheduled drugs. This creates confusion and increases her risk of mis-dosing.

Cost is a major barrier — especially for solifenacin — meaning her ability to adhere to bladder therapy is inconsistent.

She only receives blister packaging for some medications (propranolol and duloxetine), while the rest of her regimen remains unstructured, which contributes to inconsistent use.

Overall, RL’s drug therapy problems center around significant safety risks, suboptimal medication effectiveness, multiple unnecessary or outdated medications, and practical barriers to adherence.”

🌸 PLAN — WORD-FOR-WORD SPOKEN SCRIPT (NESA INCLUDED)

“Based on RL’s drug therapy problems, I have several recommendations to address her safety, improve her symptom control, and simplify her medication regimen. I’ll present these in priority order, with the rationale framed around need, effectiveness, safety, and adherence.

1. Reduce CNS Depressant Load & Rationalize Pain Therapy

Recommendation:
Begin a gradual deprescribing pathway targeting lorazepam, cyclobenzaprine, and her PRN opioids, while consolidating her opioid therapy into one formulation rather than several. Continue duloxetine and gabapentin as her primary neuropathic agents.

Rationale (NESA):

  • Need: She is currently on extremely high sedative load, which is unsafe long term.

  • Effectiveness: Opioids have limited benefit for chronic neuropathic and bladder pain.

  • Safety: Reduces risk of sedation, falls, and respiratory depression.

  • Adherence: By simplifying her pain regimen to a single scheduled medication, she will have an easier routine to follow.

Monitoring: Assess sedation, respiratory status, pain control, and withdrawal symptoms.
Follow-up: Every 1–2 weeks during tapering.

2. Optimize Bladder and OAB Management

Recommendation:
Restart solifenacin with a cost-accessible strategy (e.g., trial formulary options or coverage requests). Continue hyoscine PRN. Re-refer to pelvic floor physiotherapy. Discuss repeat Botox injection timing with urology.

Rationale (NESA):

  • Need: Bladder pain and urgency are her biggest contributors to ED visits.

  • Effectiveness: Solifenacin was previously helpful for her; PFPT improved symptoms by 50%.

  • Safety: Reducing opioid reliance improves bladder outcomes and reduces sedation.

  • Adherence: Addressing cost barriers ensures consistent use.

Monitoring: Dry mouth, constipation, urinary retention, improvement in urgency/spasms.
Follow-up: 6–8 weeks for anticholinergic effect review.

3. Improve UTI Strategy & Culture-Guided Care

Recommendation:
Obtain an updated urine culture and sensitivity at the next flare before any antibiotics. Educate RL on distinguishing bladder pain flares from true infection. Avoid unnecessary antibiotics.

Rationale (NESA):

  • Need: She has frequent UTI-like symptoms but often without infection.

  • Effectiveness: Culture-based therapy improves outcomes in patients with limited antibiotic options.

  • Safety: Avoids harmful antibiotics she is allergic to and prevents resistance.

  • Adherence: Clear guidance reduces inappropriate medication use.

Monitoring: Fever, flank pain progression, WBC count, CRP.
Follow-up: PRN at next flare; urgent reassessment if systemic signs appear.

4. Start Iron Supplementation

Recommendation:
Start oral iron therapy, ideally on alternate days, separated from PPI administration.

Rationale (NESA):

  • Need: Ferritin 20–21 indicates iron deficiency.

  • Effectiveness: Oral iron will replenish stores and improve fatigue.

  • Safety: Low risk if monitored; watch for GI upset.

  • Adherence: Simple regimen; alternate-day dosing improves tolerability.

Monitoring: Ferritin in 8–12 weeks.
Follow-up: After first course of therapy.

5. Deprescribe Unnecessary Medications

Recommendation:
Stop colchicine and vitamin B12 supplementation. Reassess ketorolac availability and restrict long-term use.

Rationale (NESA):

  • Need: These medications no longer serve an active indication.

  • Effectiveness: No therapeutic benefit currently.

  • Safety: Reduces risk of toxicity and drug interactions.

  • Adherence: Simplifies medication burden.

Monitoring: No specific labs needed. Watch for any symptom change post-discontinuation.

6. Simplify Medication Regimen

Recommendation:
Consider expanding the use of blister packs to additional medications. Consolidate PRNs where possible. Create a structured “flare plan” for bladder pain.

Rationale (NESA):

  • Need: The current regimen is overwhelming.

  • Effectiveness: Simplification improves proper dosing.

  • Safety: Reduces risk of duplicate therapy or accidental overdose.

  • Adherence: Improves daily consistency.

Monitoring: Patient-reported adherence and medication use patterns.

7. Mental Health and Binge Eating Disorder

Recommendation:
Continue duloxetine and Vyvanse. Reassess lorazepam reliance with a gradual taper plan and safety monitoring.

Rationale (NESA):

  • Need: Stable mood and functioning are key to managing chronic pain.

  • Effectiveness: Current regimen is working well.

  • Safety: Reducing benzodiazepine use decreases sedation risk.

  • Adherence: Maintaining mental health stability supports consistency across therapies.

Monitoring: Mood, anxiety, sleep quality, and lorazepam taper symptoms.